Leerink Partnrs Has Positive View of Xencor FY2025 Earnings

Xencor, Inc. (NASDAQ:XNCR) – Equities researchers at Leerink Partnrs lifted their FY2025 earnings per share (EPS) estimates for shares of Xencor in a research report issued to clients and investors on Wednesday, November 5th. Leerink Partnrs analyst J. Chang now expects that the biopharmaceutical company will earn ($2.10) per share for the year, up from their prior forecast of ($2.76). The consensus estimate for Xencor’s current full-year earnings is ($3.68) per share. Leerink Partnrs also issued estimates for Xencor’s FY2026 earnings at ($3.68) EPS.

Xencor (NASDAQ:XNCR) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.64. The firm had revenue of $21.00 million during the quarter, compared to analysts’ expectations of $29.73 million. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.75%. The company’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same period last year, the company posted ($0.71) EPS.

Several other analysts have also recently weighed in on XNCR. JPMorgan Chase & Co. cut their price objective on Xencor from $20.00 to $18.00 and set an “overweight” rating on the stock in a research report on Thursday, November 6th. Barclays upgraded Xencor from an “underweight” rating to an “overweight” rating and lifted their price target for the company from $6.00 to $23.00 in a research report on Wednesday, October 29th. Royal Bank Of Canada increased their price objective on Xencor from $18.00 to $19.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Wedbush reissued an “outperform” rating and set a $26.00 price objective on shares of Xencor in a research report on Thursday, November 6th. Finally, Bank of America downgraded shares of Xencor from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $23.00 to $12.00 in a research report on Wednesday, September 3rd. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $24.63.

Xencor Price Performance

Shares of NASDAQ XNCR opened at $14.87 on Monday. Xencor has a 1 year low of $6.92 and a 1 year high of $27.24. The stock has a market capitalization of $1.06 billion, a P/E ratio of -6.20 and a beta of 0.99. The company’s 50-day moving average is $11.95 and its 200 day moving average is $9.73.

Hedge Funds Weigh In On Xencor

A number of hedge funds have recently bought and sold shares of XNCR. Primecap Management Co. CA increased its position in Xencor by 7.9% during the second quarter. Primecap Management Co. CA now owns 10,527,322 shares of the biopharmaceutical company’s stock valued at $82,745,000 after acquiring an additional 766,310 shares during the last quarter. BVF Inc. IL grew its position in shares of Xencor by 19.7% during the 1st quarter. BVF Inc. IL now owns 2,740,141 shares of the biopharmaceutical company’s stock valued at $29,155,000 after acquiring an additional 451,381 shares during the period. Geode Capital Management LLC increased its stake in shares of Xencor by 1.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,703,664 shares of the biopharmaceutical company’s stock worth $13,393,000 after purchasing an additional 29,316 shares in the last quarter. Braidwell LP raised its holdings in Xencor by 169.0% in the 1st quarter. Braidwell LP now owns 1,655,690 shares of the biopharmaceutical company’s stock worth $17,617,000 after purchasing an additional 1,040,159 shares during the period. Finally, Bank of America Corp DE lifted its position in Xencor by 94.5% during the second quarter. Bank of America Corp DE now owns 938,993 shares of the biopharmaceutical company’s stock valued at $7,380,000 after purchasing an additional 456,302 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.